BioDelivery Sciences (NSDQ:BDSI) said today that it inked a deal with Teva Pharmaceuticals (NYSE:TEVA) to settle claims that the generic form of BioDelivery Sciences’ Bunavail buccal film that Teva is trying to bring to market in the U.S. infringes upon several patents owned by the Raleigh, N.C.-based company.
As part of the deal, which was reached in the U.S. District Court for the District of Delaware, BioDelivery Sciences made a non-exclusive license agreement with Teva permitting the pharma company to start selling its generic of the opioid dependence therapy in the U.S. beginning on July 23, 2028.
Get the full story at our sister site, Drug Delivery Business News.
